Schizophrenia/Psychosis

Exploring the connection between trauma and the etiology of schizophrenia, and the ways this connection was historically interpreted in the case of the Genain quadruplets.

What is the association between cannabis use disorders and schizophrenia? Researchers used a nationwide register-based cohort study to investigate these associations.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

“The Genain quadruplets have really gone down in psychiatric history for being the ‘poster girls’ for psychiatric genetics.”

Explore the complex interaction of cannabis and psychosis, and the sociocultural stressors and resulting neurobehavioral symptoms.

Report reviews key study results and provides updates on additional studies in development.

Awais Aftab, MD, and author Audrey Clare Farley, PhD, discuss Girls and Their Monsters: The Genain Quadruplets and the Making of Madness in America.

Awais Aftab, MD, interviews Audrey Clare Farley, PhD, author of Girls and Their Monsters: The Genain Quadruplets and the Making of Madness in America.

According to recent research, sleep problems were a common symptom in a large study of patients with first-episode psychosis.

From overutilization of emergency departments to reversible clomiphene-associated manic episodes, here are highlights from the week in Psychiatric Times.

What can we learn from sleep in schizophrenia? New research sheds light.

Although ulotaront was well-tolerated, results for patients treated with it were not superior to those for patients treated with placebo.

The experts weighed in on a wide variety of psychiatric issues for the July 2023 issue of Psychiatric Times.

“She would never hurt her baby...”

How does schizophrenia differ between men and women, and what does this mean for developing treatment strategies?

Did you miss our APA Annual Meeting coverage?

This mother shares her experience of having a loved one with schizophrenia, and the difference location can make in treatment.

The experts weighed in on a wide variety of psychiatric issues for the June 2023 issue of Psychiatric Times.

Check out the evidence for a modest effect over 1 year of clozapine dose on weight.

Should cannabis be regulated in the United States in a manner similar to alcohol and tobacco?

Researchers used an observational cohort study to investigate a potential causal association.

Researchers investigated relationships between sleep problems, suicidal ideation, and psychopathology in patients with first-episode psychosis.

The experts weighed in on a wide variety of psychiatric issues for the May 2023 issue of Psychiatric Times.

An inside look at what treatments are being discussed in San Francisco...

Data presents opportunities to enhance care and improve treatment adherence.

Research explores the differences between new-onset psychosis in patients with infection versus healthy controls.

A look at the theme for the 2023 American Psychiatric Association Annual Meeting.

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

Individuals with schizophrenia have experienced an increase in psychiatric, medical, and treatment risks because of the COVID-19 pandemic.

From new FDA treatment approvals to choosing the right levels of care in crisis stabilization units, here are highlights from the week in Psychiatric Times.